Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.

Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to...